ArticleAnnals of the New York Academy of Sciences2009
Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Article in Annals of the New York Academy of Sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Association between Catechol-O-methyltransferase rs4680 (G>A) polymorphism and lung cancer risk.Diagnostic pathology · 2014Pooled it
- Links between nocturnal hypoxia and cognitive function in breast cancer.Scientific reports · 2025Trial
- Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2018Trial
- Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.Clinical lung cancer · 2016Trial
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.Lancet (London, England) · 2009Trial
- Sex, hormones, and lung health.Physiological reviews · 2026Review
- 27-Hydroxycholesterol in bile duct tissue promotes cholangiocarcinoma progression through estrogen receptor signaling.American journal of cancer research · 2026Article
- Review
- The Mechanism of Steroid Hormones in Non-Small Cell Lung Cancer: From Molecular Signaling to Clinical Application.Biomedicines · 2025Review
- Melatonin in Chemo/Radiation Therapy; Implications for Normal Tissues Sparing and Tumor Suppression: An Updated Review.Current medicinal chemistry · 2025Review
- Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile.Frontiers in immunology · 2025Article
- The impact of hormones on lung development and function: an overlooked aspect to consider from early childhood.Frontiers in endocrinology · 2024Review
- Sex Differences in Lung Cancer.Cancers · 2023Review
- Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications.Frontiers in oncology · 2023Review
- Testosterone deficiency in male organ transplant recipients.International journal of impotence research · 2022Review
- Involvement of 27-hydroxycholesterol on the progression of non-small cell lung cancer via the estrogen receptor.American journal of cancer research · 2022Article
- Targeting Estrogens and Various Estrogen-Related Receptors against Non-Small Cell Lung Cancers: A Perspective.Cancers · 2021Review
- Role of sex hormones in lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.JTO clinical and research reports · 2021Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer has become increasingly common in women, and gender differences in the physiology and pathogenesis of the disease have suggested a role for estrogens. In the lung recent data have shown local production of estrogens from androgens via the action of aromatase enzyme and higher levels of estrogen in tumor tissue as compared with surrounding normal lung tissue. High levels of aromatase expression are also maintained in metastases as compared with primary tumors. Consistent with these findings, clinical studies suggest that aromatase expression may be a useful predictive biomarker for prognosis in the management of non-small cell lung cancer (NSCLC), the most common form of lung malignancy. Low levels of aromatase associate with a higher probability of long-term survival in older women with early stage NSCLC. Treatment of lung NSCLC xenografts in vivo with an aromatase inhibitor (exemestane) alone or combined with standard cisplatin chemotherapy elicits a significant reduction in tumor progression as compared to paired controls. Further, lung cancer progression is also governed by complex interactions between estrogen and growth factor signaling pathways to stimulate the growth of NSCLC as well as tumor-associated angiogenesis. We find that combination therapy with the multitargeted growth factor receptor inhibitor vandetanib and the estrogen receptor antagonist fulvestrant inhibit tumor growth more effectively than either treatment administered alone. Thus, incorporation of antiestrogen treatment strategies in standard antitumor therapies for NSCLC may contribute to improved patient outcome, an approach that deserves to be tested in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.